Renaissance Technologies’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Renaissance Technologies’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13,356	Closed	-$17K	–	3971
2024 Q2	$17K	Sell	13,356 -8,400	-39%	-$11.1K	﹤0.01%	3397
2024 Q1	$30K	Buy	+21,756	New	+$36K	﹤0.01%	3554
2023 Q3	–	Sell	-17,800	Closed	-$28K	–	4202
2023 Q2	$28K	Buy	+17,800	New	+$22.7K	﹤0.01%	3721
2022 Q4	–	Sell	-48,494	Closed	-$94K	–	4483
2022 Q3	$94K	Sell	48,494 -15,492	-24%	-$32.5K	﹤0.01%	3619
2022 Q2	$126K	Sell	63,986 -11,801	-16%	-$28.6K	﹤0.01%	3789
2022 Q1	$240K	Buy	75,787 +9,487	+14%	+$33.2K	﹤0.01%	3569
2021 Q4	$247K	Buy	66,300 +55,818	+533%	+$316K	﹤0.01%	3425
2021 Q3	$71K	Buy	+10,482	New	+$82K	﹤0.01%	3358

Other funds holding CYTH

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FFVM

Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies's CYTH Position: Q3 2024 in Review

Renaissance Technologies sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q3 2024, closing a stake of 13,356 shares — an estimated $17K sold.

Renaissance Technologies first reported a position in CYTH in Q3 2021 and held it in 8 quarters. The position peaked at $247K in Q4 2021. 19 funds tracked by Wall St. Rank hold CYTH as of Q3 2024.

Renaissance Technologies reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Renaissance Technologies sold 13,356 Cyclo Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $17K.
Renaissance Technologies first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Renaissance Technologies's Cyclo Therapeutics, Inc. Common Stock position peaked at $247K in Q4 2021.
19 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.